WALTERS GROUP
SEC Form 4 insider trading activity
WALTERS GROUP has filed 2 SEC Form 4 filings (2 transaction rows) across 1 company, with disclosures dating back to 2026. 2 of those filings fall inside the rolling window. Most recent filing: Aug 19, 2026.
On the most recent filing, WALTERS GROUP is listed as 10% Owner at Zentalis Pharmaceuticals, Inc. Inside the rolling window, WALTERS GROUP reported 2 open-market purchases totaling $22.9M in ZNTL and no open-market sales. The largest disclosed transaction in the window is a purchase of 4,335,000 ZNTL shares on Aug 14, 2026, worth $15.2M.
Companies traded
Other insiders at ZNTL
Insider Buying
$22.9M
reported purchases (SEC code P)
Insider Selling
$0
reported sales (SEC code S)
Companies
1
in the rolling window
Frequently asked questions
How many SEC Form 4 filings has WALTERS GROUP made?
WALTERS GROUP has filed 2 SEC Form 4 filings (2 transaction rows) across 1 company since 2026.
Which companies does WALTERS GROUP trade?
WALTERS GROUP has filed SEC Form 4 disclosures for 1 company, including ZNTL.
When was WALTERS GROUP's most recent SEC Form 4 filing?
WALTERS GROUP's most recent SEC Form 4 filing on Tracefour is dated Aug 19, 2026.
What is WALTERS GROUP's total buy and sell value in the current window?
Inside the rolling retention window, WALTERS GROUP bought $22.9M and sold $0 based on SEC Form 4 filings.
What was WALTERS GROUP's largest disclosed transaction?
The largest disclosed transaction in the current window is a purchase of 4,335,000 ZNTL shares on 2026-08-14, worth $15.2M, per SEC Form 4 filings.